Latest news articles

Added 5 hours ago Drug news

Phase III SPARTAN study of Erleada shows reduced risk of prostate cancer.- Janssen Pharma.

Janssen Pharmaceutical presented a post-hoc analysis from the Phase III SPARTAN study that showed treatment with Erleada (apalutamide) significantly reduced...

Added 2 days ago Drug news

Positive follow up data from Phase III ALEX study of Alecensa shows reduced risk of disease progression or death in ALK positive NSCLC.- Genentech/Roche

Genentech, a member of the Roche Group announced follow-up data from the Phase III ALEX study, showing that as an...

Added 2 days ago Drug news

Tecentriq + Avastin + chemotherapy shows survival advantage for first line treatment of NSCLC patients.- Genentech/Roche.

A survival advantage for the Tecentriq and Avastin combination regimen was observed in all pre-specified exploratory patient subgroups analyzed, including...

Search all news articles for Oncology
 

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Communicating Metastatic Breast Cancer Learning Zone

Communicating Metastatic Breast Cancer Learning Zone

This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.

Breakthrough Cancer Pain Learning Zone

Breakthrough Cancer Pain Learning Zone

Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

What's on the Horizon?

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 1 year ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Marshall Pearce

Cancer immunotherapies

Posted 1 year ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Guidelines

Guidelines on Penile Cancer

The European Association of Urology (EAU) Guidelines on Penile Cancer provides up-to-date information on the diagnosis and management of penile squamous cell carcinoma (SCC).

Added 4 years ago

Guidelines on Primary Urethral Carcinoma

The European Association of Urology (EAU) Guidelines Group on Muscle-invasive and Metastatic Bladder Cancer has prepared these guidelines to deliver current evidence-based information on the diagnosis and treatment of patients with...

Added 3 years ago

EAU Guidelines on Prostate Cancer

The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have prepared this guidelines document to assist medical professionals assess the evidence-based management of prostate cancer (PCa).

Added 2 years ago

Search all guidelines for Oncology
 

Journal articles

Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review.

Pemetrexed-based chemotherapy regimens (pem regimens) are the standard first-line treatment option in patients with non-squamous non-small cell lung cancer (NSCLC).

Added 4 days ago

Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer.

Pemetrexed (PEM) improves the overall survival of patients with advanced non-small cell lung cancer (NSCLC) when administered as maintenance therapy. However, PEM resistance often appears during the therapy.

Added 4 days ago

Clinical effectiveness of pemetrexed combined with cisplatin chemotherapy for advanced and maintenance treatment for patients with non-small-cell lung cancer.

Objective: To evaluate the clinical effectiveness of pemetrexed combined with cisplatin for the first-line chemotherapy of patients with advanced non-small-cell lung cancer (NSCLC) and maintenance treatment.

Added 4 days ago

Search all journal articles for Oncology
 

Clinical trials

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive...

Added 6 months ago

COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation (COLLISION)

The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable colorectal liver metastases (≤3cm) and no extrahepatic disease.

Added 6 months ago

Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study (ERASG1)

This study is aimed to evaluate the safety of applying enhanced recovery after surgery for gastric cancer.

Added 6 months ago

Search all clinical trials for Oncology
 

 

CME

Treatment Optimisation in Chronic Lymphocytic Leukaemia

Treatment Optimisation in Chronic Lymphocytic Leukaemia
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Managing the side effects of treatment for prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Managing patients at risk of prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Oncology
 

Blog Posts

Alex Keen

ELCC 2018 ‒ Roundup of this year’s conference

Posted 1 month ago

At the recent ELCC, held from 11‒14 April 2018, several hundred abstracts were presented detailing the latest cutting-edge research in lung cancer treatment and care. Brief summaries of some of the key abstracts are found here.

Alex Keen

ELCC 2018 ‒ And the Heine H. Hansen Award goes to…

Posted 1 month ago

Discover this year's Heine H. Hansen award winner, given to a scientific investigator who has made special, wide-reaching and significant contributions to lung cancer research and education, recognising their lifelong achievements.